Viewpoints
Please check back later for more content.
Advertisement
Advertisement
Trending on Modern Retina
1
FDA grants RMAT designation to RTx-015 optogenetic gene therapy for retinitis pigmentosa
2
Merck launches phase 2b/3 MALBEC trial of MK-8748 in wet AMD
3
FDA approves extended dosing intervals up to 20 weeks for EYLEA HD in wAMD and DME
4